Production of a monoclonal antibody by ascites, hollow fiber system, and transgenic plants for vaccine production using CB.Hep-1 mAb as a study case

Valdés, Rodolfo; Tamayo, Andrés; González, Marcos; Padilla, Sigifredo; Geada, Déborah; Ferro, William; Milá, Lorely; Gómez, Leonardo D.; Alemán, Rosario; Leyva, Alejandro; García, Cristina Arguedas; Mendoza, Otto; Alvarez, Tatiana; Dorta, Lamay; Villega, Yanet; Cecilia, D.; Aragón, Hasel; González, Teresita Montero; O, Maylín La; López, Jorge L.

doi:10.1007/s12257-011-0196-2

Cited by 3 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This assumption may be reasonable given the modest 3.3-fold scale-up and similarity in membrane surface area to ECS volume ratio between both cartridges (0.011 and 0.016 m 2 /mL for the small and large cartridges, respectively). A previous study reported equal mAb concentrations from using HF bioreactors of 12-mL and 2 × 60-mL ECS volume [18]. However, the study used additional supplements (low-concentration serum and ferric citrate) in the ICS media, which shorten the production time but would increase the cost.…”

Section: Scale-up Estimation and Cost Analysismentioning

confidence: 99%

“…The yield obtained from HF bioreactors can vary depending on several factors, such as the type of cells used [13,14], the size and properties of the HF membrane [15,16], the media compositions [17][18][19], and process parameters such as nutrient and waste product concentrations, flow rates [18], and harvest rates [20]. In general, the yield of products scales with the culture volume in the HF bioreactor.…”

Section: Introductionmentioning

confidence: 99%

“…In general, the yield of products scales with the culture volume in the HF bioreactor. A yield of 205 mg/month has been reported using an HF bioreactor with a 12 mL ECS volume, though up to 500 mg/month was claimed by the manufacturer [6,13,18]. Large systems, such as those with 120-160 mL of culture volume, can produce 10-25 g/month [18,21].…”

Section: Introductionmentioning

confidence: 99%

“…A yield of 205 mg/month has been reported using an HF bioreactor with a 12 mL ECS volume, though up to 500 mg/month was claimed by the manufacturer [6,13,18]. Large systems, such as those with 120-160 mL of culture volume, can produce 10-25 g/month [18,21]. Further scaling up is accomplished by running multiple cartridges in parallel.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Production of High-Value Proteins under Stringent Cost Constraints—The Case of Hollow Fiber Technology for Cell Culture

et al. 2023

View full text Add to dashboard Cite

For decades, the benefits of utilizing hollow fiber bioreactors for continuous cell culture to produce monoclonal antibodies have been widely recognized. However, the suitability of this technology for laboratories or centers with limited resources and expertise seeking to expand their production capacity is uncertain, mainly due to unknown cost-effectiveness. In this study, a hollow fiber bioreactor with a 4.7-mL culture volume was used to culture a hybridoma clone producing immunoglobulin G antibody specific to hemoglobin F (HbF). The antibody reached a maximum concentration of 1.22 g/L and totaled 21 mg over a 44-day culture period. This preliminary production data was used to estimate the cost of consumables required for using the hollow fiber bioreactor to produce 130 mg of monoclonal antibodies, which was found to be THB35.8k (£880). The cost was slightly more expensive than batch cultivation in typical culture dishes, which ranged from THB27.8 to 30.2k (£680 to 740). Despite the advantages in terms of reduced hands-on time, shorter production duration, and highly concentrated products, the primary challenges associated with using hollow fiber bioreactors were the cost and availability of the cartridges.

show abstract

Section: Scale-up Estimation and Cost Analysismentioning

confidence: 99%